GlassScriptPhysician profile
Daniel Reed Marshall
NPI 1073248829
$1,141.86
in general payments reported to CMS, 2019-2025
11 companies · $518 in 2025
The $518 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $33.32 · 2023: $34.43 · 2024: $557 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $365.48 | 2024-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $304.05 | 2024-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $158.16 | 2022-2025 | Rexulti |
| Alkermes, INC. | $90.56 | 2023-2025 | Aristada, Lybalvi |
| Corium, LLC | $62.77 | 2024-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $53.93 | 2024-2025 | Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $33.00 | 2024 | Qelbree |
| Sumitomo Pharma America, INC. | $21.41 | 2023 | Gemtesa |
| Leo Pharma INC. | $19.46 | 2022 | |
| Tris Pharma INC | $18.08 | 2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $14.96 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.